Population
Preclinical models (specific model not stated in abstract)
Comparison
Selected sympathomimetic amines vs Structural variations of the agonists
Design
Preclinical
Authors
Loading...
Suggests potential for selective cardiac sympathomimetics distinct from bronchodilators in preclinical models; leaves open clinical translation of receptor heterogeneity.
The structural requirements for sympathomimetic cardio-acceleration and increased contraction force differ from those optimal for bronchodilator action, suggesting receptor population heterogeneity.
Lands et al. (1964) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: